Risk of adverse events following oseltamivir treatment in influenza outpatients, Vaccine Safety Datalink Project, 2007-2010

Pharmacoepidemiology and Drug Safety

Volumn 22, Issue 4, 2013, Pages 335-344

  Greene, Sharon K ^a   Li, Lingling ^a   Shay, David K ^b   Fry, Alicia M ^b   Lee, Grace M ^a,c   Jacobsen, Steven J ^d   Baxter, Roger ^e   Irving, Stephanie A ^f,k   Jackson, Michael L ^g   Naleway, Allison L ^h   Nordin, James D ⁱ   Narwaney, Komal J ^j   Lieu, Tracy A ^a,c,l  

^a HARVARD MEDICAL SCHOOL   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d Kaiser Permanente Southern California ^*  (United States)

^e KAISER PERMANENTE   (United States)

^f MARSHFIELD CLINIC   (United States)

^g GROUP HEALTH RESEARCH INSTITUTE   (United States)

^h CENTER FOR HEALTH RESEARCH   (United States)

ⁱ HEALTHPARTNERS RESEARCH FOUNDATION   (United States)

^j Kaiser Permanente Colorado   (United States)

^k ABT ASSOCIATES   (United States)

^l DIVISION OF RESEARCH   (United States)

more..

Author keywords

Adverse events; Influenza; Matched cohort; Oseltamivir; Pharmacoepidemiology; Propensity scores; Psychiatric events

Indexed keywords

OSELTAMIVIR;

ADOLESCENT; ADULT; AGED; ANTIVIRAL THERAPY; ANXIETY DISORDER; ARTICLE; ATAXIA; ATTRIBUTABLE RISK; CEREBROVASCULAR ACCIDENT; CHILD; CONSCIOUSNESS DISORDER; CONVULSION; DRUG INDUCED DISEASE; DRUG SAFETY; ENCEPHALITIS; FAINTNESS; FEMALE; HUMAN; INFANT; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; OUTPATIENT; OUTPATIENT CARE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

ANTIVIRAL AGENTS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MENTAL DISORDERS; OSELTAMIVIR; RISK;

EID: 84875775602     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3363     Document Type: Article

References (44)

1. Genentech USA, Inc. Tamiflu (oseltamivir phosphate) capsules and for oral suspension [Package insert]. South San Francisco, CA: Genentech USA, Inc., 2011. Available from http://www.gene.com/gene/products/information/tamiflu/pdf/pi.pdf [4 April 2012].
2. Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM. Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60(1): 1-24.
3. U.S. Food and Drug Administration. Tamiflu (oseltamivir phosphate), 2006. Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm150758.htm [24 May 2012].
4. New concerns about oseltamivir. Lancet 2007; 369(9567): 1056.
5. U.S. Food and Drug Administration. Tamiflu (oseltamivir phosphate) capsules and for oral suspension. Detailed view: safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER) -- January 2008, 2008. Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/Safety-RelatedDrugLabelingChanges/ucm111024.htm [11 April 2012].
6. Yorifuji T, Suzuki E, Tsuda T. Oseltamivir and abnormal behaviors: true or not? Epidemiology 2009; 20(4): 619-621.
7. Okumura A, Kubota T, Kato T, Morishima T. Oseltamivir and delirious behavior in children with influenza. Pediatr Infect Dis J 2006; 25(6): 572.
8. Enger C, Nordstrom BL, Thakrar B, Sacks S, Rothman KJ. Health outcomes among patients receiving oseltamivir. Pharmacoepidemiol Drug Saf 2004; 13(4): 227-237.
9. Blumentals WA, Song X. The safety of oseltamivir in patients with influenza: analysis of healthcare claims data from six influenza seasons. MedGenMed 2007; 9(4): 23.
10. Smith JR, Sacks S. Incidence of neuropsychiatric adverse events in influenza patients treated with oseltamivir or no antiviral treatment. Int J Clin Pract 2009; 63(4): 596-605.
11. Casscells SW, Granger E, Kress AM, Linton A. The association between oseltamivir use and adverse neuropsychiatric outcomes among TRICARE beneficiaries, ages 1 through 21 years diagnosed with influenza. Int J Adolesc Med Health 2009; 21(1): 79-89.
12. Mosholder AD. Surveillance for adverse events associated with oseltamivir in a healthcare claims database. Pediatric Advisory Committee Meeting. U.S. Food and Drug Administration, May 7, 2012. Available from http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM303006.pdf [24 May 2012].
13. Fujita T, Fujii Y, Watanabe Y, et al. A pharmacoepidemiologic study on the relationship between neuropsychiatric symptoms and therapeutic drugs after influenza infection [in Japanese]. Jpn J Pharmacoepidemiol 2010; 15(2): 73-95.
14. Toovey S, Rayner C, Prinssen E, et al. Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review. Drug Saf 2008; 31(12): 1097-1114.
15. Greene SK, Shay DK, Yin R, et al. Patterns in influenza antiviral medication use before and during the 2009 H1N1 pandemic, Vaccine Safety Datalink Project, 2000-2010. Influenza Other Respi Viruses 2012; 6(6): e143-e151.
16. Donner B, Bader-Weder S, Schwarz R, Peng MM, Smith JR, Niranjan V. Safety profile of oseltamivir during the 2009 influenza pandemic. Pharmacoepidemiol Drug Saf 2011; 20(5): 532-543.
17. Menninger KA. Psychoses associated with influenza. JAMA 1919; 72(4): 235-241.
18. Morishima T, Togashi T, Yokota S, et al. Encephalitis and encephalopathy associated with an influenza epidemic in Japan. Clin Infect Dis 2002; 35(5): 512-517.
19. Maricich SM, Neul JL, Lotze TE, et al. Neurologic complications associated with influenza A in children during the 2003-2004 influenza season in Houston, Texas. Pediatrics 2004; 114(5): e626-633.
20. Bhat N, Wright JG, Broder KR, et al. Influenza-associated deaths among children in the United States, 2003-2004. N Engl J Med 2005; 353(24): 2559-2567.
21. Newland JG, Laurich VM, Rosenquist AW, et al. Neurologic complications in children hospitalized with influenza: characteristics, incidence, and risk factors. J Pediatr 2007; 150(3): 306-310.
22. Landau YE, Grisaru-Soen G, Reif S, Fattal-Valevski A. Pediatric neurologic complications associated with influenza A H1N1. Pediatr Neurol 2010; 44(1): 47-51.
23. U.S. Centers for Disease Control and Prevention. Neurologic complications associated with novel influenza A (H1N1) virus infection in children - Dallas, Texas, May 2009. MMWR Morb Mortal Wkly Rep 2009; 58(28): 773-778.
24. Lewis LL. Tamiflu (oseltamivir phosphate) pediatric safety update: Background summary and review of clinical review team activities, 2007 to present. 2012. FDA Center for Drug Evaluation and Research. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM302462.pdf [24 May 2012].
25. Baggs J, Gee J, Lewis E, et al. The Vaccine Safety Datalink: a model for monitoring immunization safety. Pediatrics 2011; 127(1): S45-53.
26. Mullooly J, Drew L, DeStefano F, et al. Quality assessments of HMO diagnosis databases used to monitor childhood vaccine safety. Methods Inf Med 2004; 43(2): 163-170.
27. U.S. Centers for Disease Control and Prevention. Swine influenza A (H1N1) infection in two children--Southern California, March-April 2009. MMWR Morb Mortal Wkly Rep 2009; 58(15): 400-402.
28. Lipsitch M, Tchetgen E, Cohen T. Negative controls: a tool for detecting confounding and bias in observational studies. Epidemiology 2010; 21(3): 383-388.
29. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1984; 79(387): 516-524.
30. Sekhon JS. Multivariate and propensity score matching software with automated balance optimization: the matching package for R. J Stat Software 2011; 42(7): 1-52.
31. Noah MA, Peek GJ, Finney SJ, et al. Referral to an extracorporeal membrane oxygenation center and mortality among patients with severe 2009 influenza A(H1N1). JAMA 2011; 306(15): 1659-1668.
32. Mamdani M, Sykora K, Li P, et al. Reader's guide to critical appraisal of cohort studies: 2. Assessing potential for confounding. Br Med J 2005; 330(7497): 960-962.
33. Tse A, Tseng HF, Greene SK, Vellozzi C, Lee GM. Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011. Vaccine 2012; 30(11): 2024-2031.
34. Hama R. Fatal neuropsychiatric adverse reactions to oseltamivir: Case series and overview of causal relationships. Int J Risk Saf Med 2008; 20: 5-36.
35. Nakamura K, Schwartz BS, Lindegardh N, Keh C, Guglielmo BJ. Possible neuropsychiatric reaction to high-dose oseltamivir during acute 2009 H1N1 influenza A infection. Clin Infect Dis 2010; 50(7): e47-49.
36. Johann-Liang R, Mosholder A. Tamiflu[R] (oseltamivir) Safety Update. Pediatric Advisory Committee Meeting. FDA Center for Drug Evaluation and Research, November 16, 2006. Available from: www.fda.gov/ohrms/dockets/AC/06/slides/2006-4254s_09_Johann-Liang_Tamiflu.ppt [15 November 2011].
37. R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2009. ISBN: 3-900051-07-0, URL http://www.R-project.org
38. Urushihara H, Doi Y, Arai M, et al. Oseltamivir prescription and regulatory actions vis-a-vis abnormal behavior risk in Japan: drug utilization study using a nationwide pharmacy database. PLoS One 2011; 6(12): e28483.
39. Rowhani-Rahbar A, Klein NP, Dekker CL, et al. Biologically plausible and evidence-based risk intervals in immunization safety research. Vaccine 2012. [Epub ahead of print].
40. Pariente A, Gregoire F, Fourrier-Reglat A, Haramburu F, Moore N. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf 2007; 30(10): 891-898.
41. Townsend L, Walkup JT, Crystal S, Olfson M. A systematic review of validated methods for identifying depression using administrative data. Pharmacoepidemiol Drug Saf 2012; 21(1): 163-173.
42. Walkup JT, Townsend L, Crystal S, Olfson M. A systematic review of validated methods for identifying suicide or suicidal ideation using administrative or claims data. Pharmacoepidemiol Drug Saf 2012; 21(1): 174-182.
43. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40(5): 373-383.
44. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45(6): 613-619.